RDA Financial Network raised its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 497.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 64,994 shares of the biopharmaceutical company’s stock after purchasing an additional 54,124 shares during the quarter. RDA Financial Network’s holdings in Pfizer were worth $1,724,000 as of its most recent SEC filing.
Several other hedge funds also recently modified their holdings of the company. Gladius Capital Management LP grew its stake in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the last quarter. Quarry LP bought a new stake in Pfizer during the second quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new position in Pfizer in the third quarter worth approximately $35,000. Joseph Group Capital Management increased its holdings in shares of Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 771 shares in the last quarter. Finally, Kennebec Savings Bank acquired a new stake in shares of Pfizer during the 3rd quarter valued at $50,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities analysts recently issued reports on PFE shares. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Guggenheim dropped their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Citigroup began coverage on shares of Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective for the company. Sanford C. Bernstein started coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $32.00.
Insider Transactions at Pfizer
In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by company insiders.
Pfizer Trading Up 1.1 %
Pfizer stock opened at $26.51 on Friday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $150.20 billion, a P/E ratio of 35.82, a P/E/G ratio of 0.64 and a beta of 0.64. The company’s fifty day simple moving average is $26.11 and its 200-day simple moving average is $28.01.
Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The business’s quarterly revenue was up 31.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.94 EPS for the current fiscal year.
Pfizer Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.49%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is currently 227.03%.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Five stocks we like better than Pfizer
- Insider Trades May Not Tell You What You Think
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Conference Calls and Individual Investors
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
- How to Effectively Use the MarketBeat Ratings Screener
- Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.